Accelaffin™
The Accelaffin™ microfluidic processor represents a breakthrough in biochip hybridisation technology.
Hybridisation is a critical step in the successful use of polynucleotide arrays. A range of systems currently available aim to automate this step, in order to make it more reliable and reproduceable.
The hybridisation step has, however, increasingly become a bottleneck in the Biochip assay process. In general, hybridisation reactions take about 4 to 12 hours (up to 48 hours for some expression protocols). Any reduction in this “dead time” would benefit the throughput for all applications and offer even greater potential benefits in the diagnostic and point-of-care markets.
The Accelaffin™ processor leverages advances in microfluidic and biophysical technologies and can reduce hybridisation times to less than 10 minutes. This will substantially increase the throughput of hybridisation platforms.
The Accelaffin™ microfluidic process can potentially be installed on all biochip processor systems. This includes DNA and RNA chips, proteomic chips, as well as more sophisticated “hybrid” array systems.
To help biochip users to gain access to the Accelaffin™ technology, Mobious is making the processor available on a number of popular commercial automated hybridisation platforms. Currently available systems upgraded with the Accelaffin™ microfluidic processor are the Tecan HS 400 ProTM and HS 4800 ProTM. Please follow the link for product specifications.
The next systems to be available with Accelaffin™ technology will the Genomic Solutions HybStationTM and Hyb4 Hybridisation stations (link).
Users of Tecan or Genomic Solutions hybridisation systems who would like to upgrade and/or those interested in applying Accelaffin™ to their platform or application should contact us for a quotation.
The Accelaffin™ microfluidic processor represents a breakthrough in biochip hybridisation technology.
Hybridisation is a critical step in the successful use of polynucleotide arrays. A range of systems currently available aim to automate this step, in order to make it more reliable and reproduceable.
The hybridisation step has, however, increasingly become a bottleneck in the Biochip assay process. In general, hybridisation reactions take about 4 to 12 hours (up to 48 hours for some expression protocols). Any reduction in this “dead time” would benefit the throughput for all applications and offer even greater potential benefits in the diagnostic and point-of-care markets.
The Accelaffin™ processor leverages advances in microfluidic and biophysical technologies and can reduce hybridisation times to less than 10 minutes. This will substantially increase the throughput of hybridisation platforms.
The Accelaffin™ microfluidic process can potentially be installed on all biochip processor systems. This includes DNA and RNA chips, proteomic chips, as well as more sophisticated “hybrid” array systems.
To help biochip users to gain access to the Accelaffin™ technology, Mobious is making the processor available on a number of popular commercial automated hybridisation platforms. Currently available systems upgraded with the Accelaffin™ microfluidic processor are the Tecan HS 400 ProTM and HS 4800 ProTM. Please follow the link for product specifications.
The next systems to be available with Accelaffin™ technology will the Genomic Solutions HybStationTM and Hyb4 Hybridisation stations (link).
Users of Tecan or Genomic Solutions hybridisation systems who would like to upgrade and/or those interested in applying Accelaffin™ to their platform or application should contact us for a quotation.